We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Levels of Vitamin B12 May Indicate Cancer Risk

By LabMedica International staff writers
Posted on 05 Dec 2013
A substantial proportion of patients referred for plasma vitamin B12 (cobalamin [Cbl]) measurement present with high Cbl levels, which have been reported in patients with different cancer types.

Vitamin B12 is essential for maintaining healthy bodily function, but higher than normal levels using a reference range of 200 pmol/L to 600 pmol/L may indicate that a patient is at risk of developing certain cancers.

Scientists at the Aarhus University Hospital (Denmark) conducted a cohort study using population-based Danish medical registries. More...
They reviewed the records of 333,667 patients without cancer who had been referred for Cbl testing to estimate the incidence of cancer in this population from 1998 to 2010. Patients referred for Cbl measurement with levels greater than the lower reference limit of equal to or greater than 200 pmol/L were identified from the population.

Of the patients included in the study, 19,665 (6%) had levels greater than the upper reference limit of greater than 600 pmol/L. The total number of person-years of follow-up was 1,421,512 and median follow-up time was 3.5 years. The median age was 55.1 years. The distribution of outpatients and inpatients was 276,229 (83%) and 57,438 (17%), respectively. A total of 22,652 (7%) patients in the study cohort subsequently developed cancer during the period from 1998 to 2010.

The investigators found that the risk of cancer overall increased with higher Cbl levels, especially during the first year after measurement and for those with levels greater than 800 pmol/L. They also found that after five years of follow-up, the risk for hematological and alcohol and smoking-related cancers remained high for those with levels greater than 800 pmol/L. The cancer risk remained elevated after the first year of follow-up for liver, pancreatic, lung cancer, and myeloid malignancies, with highest standardized incidence ratios observed for patients with Cbl levels greater than 800 pmol/L.

The authors concluded that high plasma Cbl levels increased the risk of subsequently diagnosed cancer, mostly within the first year of follow-up. However, this association was not present for all cancer types. Although their results may have clinical implications for interpreting high Cbl levels, further studies are warranted to examine the possible diagnostic value of high plasma Cbl levels. The study was published on November 18, 2013, in the Journal of the National Cancer Institute.

Related Links:

Aarhus University Hospital



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.